TOBREX
LOE ApproachingNDAOPHTHALMICOINTMENT
Approved
Nov 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOBREX (tobramycin) is an aminoglycoside antibacterial ointment approved for ophthalmic use since 1981. It treats bacterial eye infections by inhibiting bacterial protein synthesis. The drug is formulated as a topical ointment for direct ocular application.
LOE Approaching
Product is in late lifecycle stage with moderate competitive pressure (60%), signaling a mature, stable team focused on defense and cost management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle
Started Dec 2006
0Post-surgical Inflammation
Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects
Started Sep 2005
98 enrolled
Cystic Fibrosis
Career Relevance
TOBREX offers limited career growth opportunities due to its LOE-approaching status and zero linked job openings; roles focus on defensive brand management, pricing strategy, and customer retention. Career progression on this product is best suited for professionals seeking stability in a mature franchise rather than high-impact launch or expansion opportunities.
Brand Manager
Worked on TOBREX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.